India Diabetes Care Drugs Market Trends

Statistics for the 2023 & 2024 India Diabetes Care Drugs market trends, created by Mordor Intelligence™ Industry Reports. India Diabetes Care Drugs trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Trends of India Diabetes Care Drugs Industry

Oral-Anti Diabetes Drugs Segment is Having the Highest Market Share in the Current Year

Diabetes is a disorder for which there is no cure. With the present arsenal, it is an illness that impacts us for the rest of patients' lives. Individuals face a significant financial, social, and emotional burden beginning at 30 and continuing into their 90s. According to all current guidelines in India, metformin should be the first option among oral antidiabetic medicines at the outset of diabetes.

However, a review of the literature from around the world finds that metformin is used in various ways in the early stages of diabetes. Sharma et al. found a changing trend in 55% of metformin-treated individuals. The fraction of individuals on metformin remains stable from 0 to 20 years of diabetes. 

The proportion of sulfonylurea and dipeptidyl peptidase-4 inhibitors (DPP4i) increases from 23.12% and 22.5% in 0-5 years of diabetes to 70.77% and 60% in 10-15 years of diabetes. Following that, the proportion of sulfonylurea and DPP4i remains constant. As the use of sulfonylureas and DPP4i reaches a plateau, the use of insulin and sodium/glucose cotransporter 2 inhibitors increases. From 5 to 10 years of diabetes duration to 20+ years of diabetes duration, the proportion of alpha-glucosidase inhibitors increases somewhat. Thiazolidinediones and glucagon-like peptide-1 receptor agonists have a small proportion in contemporary practice and the given patient population.

Through the Indian government's encouragement, the usage of drugs increased over the forecast period.

India Diabetes Care Drugs Market: Volume CAGR (in %), By Drugs, 2023-2028

The rising prevalence of diabetes in India is boosting the country's diabetes drugs market.

People living in cities and metropolitan regions in India are more likely than ever before to get diabetes, according to the 2022 assessment. This is due, in part, to cities encouraging a lifestyle that might raise a person's BMI (BMI). A greater BMI is a risk factor for diabetes. Rural India is also seeing an increase in type 2 diabetes occurrences. Diabetes is perceived as a "new" ailment in rural places, and public understanding of the condition is poor.

Diabetes cases are several as the country undergoes urbanization, so more people are migrating to larger cities for work. Sedentary living habits are promoted in urbanized regions and cities, which is a risk factor for rising obesity and diabetes. South Asian ancestors' bodies respond differently to sugary and fatty diets than European ancestors' bodies, and as processed Western foods become more popular in India, so does the risk of diabetes.

In India, it is anticipated to exceed 134 million by 2045. Approximately 57% of these people are still undiagnosed. Type 2 diabetes accounts for most behavioral behaviors and can result in multiorgan problems, roughly classified as microvascular and macrovascular complications. These problems are a key cause of increased early morbidity and death in diabetics, resulting in decreased life expectancy and a huge financial load on the Indian healthcare system. 

Thus, the above factors are expected to drive the market growth over the forecast period.

India Diabetes Care Drugs Market, Diabetes Population (in million), India, 2017-2022

India Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)